To evaluate the therapeutic potential of KAT2A inhibition, we sought to induce the KAT2A knockdown after the formation of 3D spheroids, mimicking the clinical scenario in which most CRCs are diagnosed at advanced stage when complex 3D tumor structures are already established [35]. The gene discussed is KAT2A; the disease is neoplasm.